EpimAb Biotherapeutics, a Shanghai-based biopharmaceutical company specializing in bispecific antibodies, announced on Wednesday the closing of a US$74 million series B round of financing jointly led by Chinese private equity fund manager SDIC Fund, and pharmaceutical and biotech-focused Sherpa Healthcare Partners. The investment took the total capital raised by EpimAb to over US$100 million, said […]

Chinese Biopharmaceutical Start-Up EpimAb Closes $74M Series B Round comes originally from China Money Network. All Rights Reserved.